<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>Summarize safety data — asr_safety_summary • SwissASR</title><!-- favicons --><link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png"><link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png"><link rel="apple-touch-icon" type="image/png" sizes="180x180" href="../apple-touch-icon.png"><link rel="apple-touch-icon" type="image/png" sizes="120x120" href="../apple-touch-icon-120x120.png"><link rel="apple-touch-icon" type="image/png" sizes="76x76" href="../apple-touch-icon-76x76.png"><link rel="apple-touch-icon" type="image/png" sizes="60x60" href="../apple-touch-icon-60x60.png"><script src="../lightswitch.js"></script><script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><link href="../deps/bootstrap-5.3.1/bootstrap.min.css" rel="stylesheet"><script src="../deps/bootstrap-5.3.1/bootstrap.bundle.min.js"></script><link href="../deps/font-awesome-6.5.2/css/all.min.css" rel="stylesheet"><link href="../deps/font-awesome-6.5.2/css/v4-shims.min.css" rel="stylesheet"><script src="../deps/headroom-0.11.0/headroom.min.js"></script><script src="../deps/headroom-0.11.0/jQuery.headroom.min.js"></script><script src="../deps/bootstrap-toc-1.0.1/bootstrap-toc.min.js"></script><script src="../deps/clipboard.js-2.0.11/clipboard.min.js"></script><script src="../deps/search-1.0.0/autocomplete.jquery.min.js"></script><script src="../deps/search-1.0.0/fuse.min.js"></script><script src="../deps/search-1.0.0/mark.min.js"></script><!-- pkgdown --><script src="../pkgdown.js"></script><meta property="og:title" content="Summarize safety data — asr_safety_summary"><meta name="description" content="This function creates the text and summary table for the report."><meta property="og:description" content="This function creates the text and summary table for the report."><meta property="og:image" content="https://ctu-bern.github.io/SwissASR/logo.png"></head><body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>


    <nav class="navbar navbar-expand-lg fixed-top " aria-label="Site navigation"><div class="container">

    <a class="navbar-brand me-2" href="../index.html">SwissASR</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">0.5.3</small>


    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto"><li class="active nav-item"><a class="nav-link" href="../reference/index.html">Reference</a></li>
<li class="nav-item"><a class="nav-link" href="../news/index.html">Changelog</a></li>
      </ul><ul class="navbar-nav"><li class="nav-item"><form class="form-inline" role="search">
 <input class="form-control" type="search" name="search-input" id="search-input" autocomplete="off" aria-label="Search site" placeholder="Search for" data-search-index="../search.json"></form></li>
<li class="nav-item"><a class="external-link nav-link" href="https://github.com/CTU-Bern/SwissASR/" aria-label="GitHub"><span class="fa fab fa-github fa-lg"></span></a></li>
      </ul></div>


  </div>
</nav><div class="container template-reference-topic">
<div class="row">
  <main id="main" class="col-md-9"><div class="page-header">
      <img src="../logo.png" class="logo" alt=""><h1>Summarize safety data</h1>
      <small class="dont-index">Source: <a href="https://github.com/CTU-Bern/SwissASR/blob/main/R/asr_safety_summary.R" class="external-link"><code>R/asr_safety_summary.R</code></a></small>
      <div class="d-none name"><code>asr_safety_summary.Rd</code></div>
    </div>

    <div class="ref-description section level2">
    <p>This function creates the text and summary table for the report.</p>
    </div>

    <div class="section level2">
    <h2 id="ref-usage">Usage<a class="anchor" aria-label="anchor" href="#ref-usage"></a></h2>
    <div class="sourceCode"><pre class="sourceCode r"><code><span><span class="fu">asr_safety_summary</span><span class="op">(</span><span class="va">data</span>, <span class="va">period_data</span>, <span class="va">trial_type</span>, <span class="va">n_pat_e</span>, <span class="va">n_per_arm</span><span class="op">)</span></span></code></pre></div>
    </div>

    <div class="section level2">
    <h2 id="arguments">Arguments<a class="anchor" aria-label="anchor" href="#arguments"></a></h2>


<dl><dt id="arg-data">data<a class="anchor" aria-label="anchor" href="#arg-data"></a></dt>
<dd><p>SAE data</p></dd>


<dt id="arg-period-data">period_data<a class="anchor" aria-label="anchor" href="#arg-period-data"></a></dt>
<dd><p>SAE data restricted to a specific period</p></dd>


<dt id="arg-trial-type">trial_type<a class="anchor" aria-label="anchor" href="#arg-trial-type"></a></dt>
<dd><p>trial type (<code>imp</code>, <code>medical device</code> or <code>other</code>)</p></dd>


<dt id="arg-n-pat-e">n_pat_e<a class="anchor" aria-label="anchor" href="#arg-n-pat-e"></a></dt>
<dd><p>Number of enrolled participants</p></dd>


<dt id="arg-n-per-arm">n_per_arm<a class="anchor" aria-label="anchor" href="#arg-n-per-arm"></a></dt>
<dd><p>Number of participants enrolled per arm</p></dd>

</dl></div>
    <div class="section level2">
    <h2 id="value">Value<a class="anchor" aria-label="anchor" href="#value"></a></h2>

<dl><dt>txt</dt>
<dd><p>The sentences required for the report</p></dd>

<dt>tab</dt>
<dd><p>The summary table required for the report</p></dd>

<dt>tab_map</dt>
<dd><p>Mapping between the variable name in <code>tab</code> and a nicer label</p></dd>


</dl></div>

    <div class="section level2">
    <h2 id="ref-examples">Examples<a class="anchor" aria-label="anchor" href="#ref-examples"></a></h2>
    <div class="sourceCode"><pre class="sourceCode r"><code><span class="r-in"><span><span class="fu"><a href="https://rdrr.io/r/utils/data.html" class="external-link">data</a></span><span class="op">(</span><span class="va">asr_sae</span><span class="op">)</span></span></span>
<span class="r-in"><span><span class="co"># IMP</span></span></span>
<span class="r-in"><span><span class="va">prepped</span> <span class="op">&lt;-</span> <span class="fu"><a href="asr_dataprep.html">asr_dataprep</a></span><span class="op">(</span><span class="va">asr_sae</span>,</span></span>
<span class="r-in"><span>                        period_from <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/as.Date.html" class="external-link">as.Date</a></span><span class="op">(</span><span class="st">"2020-10-10"</span><span class="op">)</span>,</span></span>
<span class="r-in"><span>                        period_to <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/as.Date.html" class="external-link">as.Date</a></span><span class="op">(</span><span class="st">"2021-10-10"</span><span class="op">)</span></span></span>
<span class="r-in"><span>                        <span class="op">)</span></span></span>
<span class="r-in"><span><span class="fu">asr_safety_summary</span><span class="op">(</span>data <span class="op">=</span> <span class="va">prepped</span><span class="op">$</span><span class="va">data</span>, period_data <span class="op">=</span> <span class="va">prepped</span><span class="op">$</span><span class="va">period_data</span>,</span></span>
<span class="r-in"><span>                   <span class="st">"imp"</span>, <span class="fl">60</span>, n_per_arm <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/list.html" class="external-link">list</a></span><span class="op">(</span>grp1 <span class="op">=</span> <span class="fl">150</span>, grp2 <span class="op">=</span> <span class="fl">150</span><span class="op">)</span><span class="op">)</span></span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $txt</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [1] "During the reporting period, 20 of 60 participants (33.3 %) reported a total of 20 serious adverse events (SAEs)."                                           </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [2] "9 of 20 SAEs (45.0 %) were classified 'related' to the IMP."                                                                                                 </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [3] "Most frequent related SAEs (i.e., SADR.) documented were poor sleep (3), spontaneous unconsciousness (3), headache (2)."                                     </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [4] "6 Suspected Unexpected Serious Adverse Reactions (SUSARs) occurred during the reporting period, which have been notified to the Swiss competent authorities."</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $txt_all</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [1] "Since the beginning of the study, 20 of 60 participants (33.3 %) reported a total of 20 serious adverse events (SAEs)."                                      </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [2] "9 of 20 SAEs (45.0 %) were classified 'related' to the IMP."                                                                                                 </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [3] "Most frequent related SAEs (i.e., SADR.) documented were poor sleep (3), spontaneous unconsciousness (3), headache (2)."                                     </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [4] "6 Suspected Unexpected Serious Adverse Reactions (SUSARs) occurred during the reporting period, which have been notified to the Swiss competent authorities."</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $tab</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> <span style="color: #949494;"># A tibble: 2 × 5</span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   desc                                                   fatal   sae  sadr susar</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span>                                                  <span style="color: #949494; font-style: italic;">&lt;int&gt;</span> <span style="color: #949494; font-style: italic;">&lt;int&gt;</span> <span style="color: #949494; font-style: italic;">&lt;int&gt;</span> <span style="color: #949494; font-style: italic;">&lt;int&gt;</span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span> <span style="color: #BCBCBC;">1</span> Number of cases (during reporting period)                  0    20     5     6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> <span style="color: #BCBCBC;">2</span> Number of cases (cumulative) since the start of the c…     3    17     5     6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $tab_map</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   col_key</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 1    desc</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 2   fatal</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 3     sae</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 4    sadr</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 5   susar</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                                                                     name</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 1                                                                    IMP</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 2                       Serious Adverse Events, SAEs, with fatal outcome</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 3                           Other Serious Adverse Events, non-fatal SAEs</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 4                  Serious Adverse Drug Reactions, SADRs (only for IMPs)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 5 Suspected Unexpected Serious Adverse Reactions, SUSARs (only for IMPs)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-in"><span></span></span>
<span class="r-in"><span><span class="co"># medical devices</span></span></span>
<span class="r-in"><span><span class="va">prepped</span> <span class="op">&lt;-</span> <span class="fu"><a href="asr_dataprep.html">asr_dataprep</a></span><span class="op">(</span><span class="va">asr_sae</span>, period_from <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/as.Date.html" class="external-link">as.Date</a></span><span class="op">(</span><span class="st">"2020-10-10"</span><span class="op">)</span>,</span></span>
<span class="r-in"><span>                        period_to <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/as.Date.html" class="external-link">as.Date</a></span><span class="op">(</span><span class="st">"2021-10-10"</span><span class="op">)</span>, trial_type <span class="op">=</span> <span class="st">"m"</span><span class="op">)</span></span></span>
<span class="r-in"><span><span class="fu">asr_safety_summary</span><span class="op">(</span>data <span class="op">=</span> <span class="va">prepped</span><span class="op">$</span><span class="va">data</span>,</span></span>
<span class="r-in"><span>                           period_data <span class="op">=</span> <span class="va">prepped</span><span class="op">$</span><span class="va">period_data</span>, <span class="st">"m"</span>, <span class="fl">60</span>,</span></span>
<span class="r-in"><span>                            n_per_arm <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/list.html" class="external-link">list</a></span><span class="op">(</span>grp1 <span class="op">=</span> <span class="cn">NA</span>, grp2 <span class="op">=</span> <span class="cn">NA</span><span class="op">)</span><span class="op">)</span></span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $txt</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [1] "During the reporting period, a total of 20 serious adverse events (SAEs) have been reported."                                                                                                                                                   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [2] "9 out of 20 SAEs (45.0 %) were classified ''related'' to the MD or to an intervention (procedure) undertaken in the clinical trial."                                                                                                            </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [3] "In 7 of 20 SAEs (35.0 %) it cannot be excluded that the events are attributable to the medical device under investigation."                                                                                                                     </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [4] "In 12 of 20 SAEs (60.0 %) it cannot be excluded that the events are attributable to an intervention undertaken in the clinical trial."                                                                                                          </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [5] "The most frequent SAEs documented were spontaneous unconsciousness (7), headache (5), poor sleep (4)."                                                                                                                                          </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [6] "Occurrence of SAE in the trial arm versus control arm (if applicable)."                                                                                                                                                                         </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [7] "With respect to the expectedness of the event, 4 (44.4 %) of the SADEs were expected/anticipated and 5 (144.4 %) were classified as unexpected/unanticipated."                                                                                  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [8] "11 device deficiencies were observed (includes malfunctions, use errors, inadequacies in the information supplied by the manufacturer including labelling)."                                                                                    </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [9] "11 out of 11 device deficiencies (100.0 %) could have led to serious adverse events if suitable action had not been taken, intervention had not been made, or circumstances had been less fortunate (device deficiencies with a SAE potential)."</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [10] "12 health hazards that required safety-related measures occurred."                                                                                                                                                                              </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [11] "Safety and protective measures taken by the investigator/sponsor (including those requested by the ethics committee and Swissmedic and authorities abroad) taken in Switzerland and abroad: [free text]"                                        </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $txt_all</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [1] "During the reporting period, a total of 20 serious adverse events (SAEs) have been reported."                                                                                                                                                   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [2] "9 out of 20 SAEs (45.0 %) were classified ''related'' to the MD or to an intervention (procedure) undertaken in the clinical trial."                                                                                                            </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [3] "In 7 of 20 SAEs (35.0 %) it cannot be excluded that the events are attributable to the medical device under investigation."                                                                                                                     </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [4] "In 12 of 20 SAEs (60.0 %) it cannot be excluded that the events are attributable to an intervention undertaken in the clinical trial."                                                                                                          </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [5] "The most frequent SAEs documented were spontaneous unconsciousness (7), headache (5), poor sleep (4)."                                                                                                                                          </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [6] "Occurrence of SAE in the trial arm versus control arm (if applicable)."                                                                                                                                                                         </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [7] "With respect to the expectedness of the event, 4 (44.4 %) of the SADEs were expected/anticipated and 5 (144.4 %) were classified as unexpected/unanticipated."                                                                                  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [8] "11 device deficiencies were observed (includes malfunctions, use errors, inadequacies in the information supplied by the manufacturer including labelling)."                                                                                    </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [9] "11 out of 11 device deficiencies (100.0 %) could have led to serious adverse events if suitable action had not been taken, intervention had not been made, or circumstances had been less fortunate (device deficiencies with a SAE potential)."</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [10] "12 health hazards that required safety-related measures occurred."                                                                                                                                                                              </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [11] "Safety and protective measures taken by the investigator/sponsor (including those requested by the ethics committee and Swissmedic and authorities abroad) taken in Switzerland and abroad: [free text]"                                        </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $tab</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> <span style="color: #949494;"># A tibble: 2 × 4</span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   desc                                                       sade  attr measures</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span>                                                     <span style="color: #949494; font-style: italic;">&lt;int&gt;</span> <span style="color: #949494; font-style: italic;">&lt;int&gt;</span>    <span style="color: #949494; font-style: italic;">&lt;int&gt;</span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span> <span style="color: #BCBCBC;">1</span> Number of cases (during reporting period)                     0     7       12</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> <span style="color: #BCBCBC;">2</span> Number of cases (cumulative) since the start of the clin…     0     7       12</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $tab_map</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   col_key</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 1    desc</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 2    sade</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 3   fatal</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 4     sae</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                                                                       name</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 1                                                            MD/IVD Device</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 2                                      Serious Adverse Device Effects SADE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 3 Device Deficiencies that could have led to an SAE (serious deficiencies)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 4          Safety and protective measures taken in Switzerland and abroad.</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-in"><span></span></span>
<span class="r-in"><span><span class="co"># other trial</span></span></span>
<span class="r-in"><span><span class="fu">asr_safety_summary</span><span class="op">(</span>data <span class="op">=</span> <span class="va">prepped</span><span class="op">$</span><span class="va">data</span>, period_data <span class="op">=</span> <span class="va">prepped</span><span class="op">$</span><span class="va">period_data</span>, <span class="st">"o"</span>, <span class="fl">60</span>,</span></span>
<span class="r-in"><span> n_per_arm <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/list.html" class="external-link">list</a></span><span class="op">(</span>grp1 <span class="op">=</span> <span class="fl">150</span>, grp2 <span class="op">=</span> <span class="fl">150</span><span class="op">)</span><span class="op">)</span></span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $txt</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [1] "During the reporting period, 20 of 60 participants (33.3 %) reported a total of 20 serious adverse events (SAEs) with possible relationship to the study intervention)."</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [2] "The most frequent documented SAEs with possible relationship to the intervention were poor sleep (3), spontaneous unconsciousness (3), headache (2)."                   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $txt_all</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [1] "Since the beginning of the study, 20 of 60 participants (33.3 %) reported a total of 20 serious adverse events (SAEs) with possible relationship to the study intervention)."</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [2] "The most frequent documented SAEs with possible relationship to the intervention were poor sleep (3), spontaneous unconsciousness (3), headache (2)."                        </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $tab</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> <span style="color: #949494;"># A tibble: 2 × 3</span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   desc                                                              fatal nfatal</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span>                                                             <span style="color: #949494; font-style: italic;">&lt;int&gt;</span>  <span style="color: #949494; font-style: italic;">&lt;int&gt;</span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span> <span style="color: #BCBCBC;">1</span> Number of cases (during reporting period)                             0      9</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> <span style="color: #BCBCBC;">2</span> Number of cases (cumulative) since the start of the clinical tri…     1      8</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $tab_map</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   col_key</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 1    desc</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 2   fatal</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 3     sae</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                                                                               name</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 1                                                             Other clinical trial</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 2 SAEs with fatal outcome where a causality to the intervention cannot be excluded</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 3              Other SAEs where a causality to the intervention cannot be excluded</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-in"><span></span></span>
<span class="r-in"><span><span class="co"># tpr trial</span></span></span>
<span class="r-in"><span><span class="fu">asr_safety_summary</span><span class="op">(</span>data <span class="op">=</span> <span class="va">prepped</span><span class="op">$</span><span class="va">data</span>, period_data <span class="op">=</span> <span class="va">prepped</span><span class="op">$</span><span class="va">period_data</span>, <span class="st">"t"</span>, <span class="fl">60</span>,</span></span>
<span class="r-in"><span> n_per_arm <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/list.html" class="external-link">list</a></span><span class="op">(</span>grp1 <span class="op">=</span> <span class="fl">150</span>, grp2 <span class="op">=</span> <span class="fl">150</span><span class="op">)</span><span class="op">)</span></span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $txt</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [1] "During the reporting period, a total of 20 Serious Adverse Events (SAEs) occurred."                                                                                                                      </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [2] "9 of 20 SAEs (45.0 %) were classified as Serious Adverse Drug Reaction (SADR) i.e., serious adverse events with possible relationship to the TrP/GT/GMO administered."                                   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [3] "The most frequent SADR documented were spontaneous unconsciousness (7), headache (5), poor sleep (4)."                                                                                                   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [4] "In 3 out of 5 SADRs (60.0 %) it cannot be excluded that the events are attributable to the TrP/GT/GMO itself."                                                                                           </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [5] "In 2 out of 5 SADRs (40.0 %) it cannot be excluded that the events are attributable to other factors like quality defects, contaminations, administration and preparation procedures of TrP/GT/GMO, etc."</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [6] "6 Suspected Unexpected Serious Adverse Reactions (SUSARs) occurred during the reporting period."                                                                                                         </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [7] "Other new relevant safety aspects (including details regarding exposure): "                                                                                                                              </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $txt_all</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [1] "Since the beginning of the study, a total of 20 Serious Adverse Events (SAEs) occurred."                                                                                                                 </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [2] "9 of 20 SAEs (45.0 %) were classified as Serious Adverse Drug Reaction (SADR) i.e., serious adverse events with possible relationship to the TrP/GT/GMO administered."                                   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [3] "The most frequent SADR documented were spontaneous unconsciousness (7), headache (5), poor sleep (4)."                                                                                                   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [4] "In 3 out of 5 SADRs (60.0 %) it cannot be excluded that the events are attributable to the TrP/GT/GMO itself."                                                                                           </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [5] "In 2 out of 5 SADRs (40.0 %) it cannot be excluded that the events are attributable to other factors like quality defects, contaminations, administration and preparation procedures of TrP/GT/GMO, etc."</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [6] "6 Suspected Unexpected Serious Adverse Reactions (SUSARs) occurred during the reporting period."                                                                                                         </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [7] "Other new relevant safety aspects (including details regarding exposure): "                                                                                                                              </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $tab</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> <span style="color: #949494;"># A tibble: 2 × 6</span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   desc                                            fatal nfatal nsadr  sadr susar</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span>                                           <span style="color: #949494; font-style: italic;">&lt;int&gt;</span>  <span style="color: #949494; font-style: italic;">&lt;int&gt;</span> <span style="color: #949494; font-style: italic;">&lt;int&gt;</span> <span style="color: #949494; font-style: italic;">&lt;int&gt;</span> <span style="color: #949494; font-style: italic;">&lt;int&gt;</span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span> <span style="color: #BCBCBC;">1</span> Number of cases (during reporting period)           0     20     0     5     6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> <span style="color: #BCBCBC;">2</span> Number of cases (cumulative) since the start o…     3     17     0     5     6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $tab_map</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   col_key                                                   name</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 1    desc                                                       </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 2   fatal                                SAEs with fatal outcome</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 3  nfatal          Other Serious Adverse Events (non-fatal SAEs)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 4   nsadr             Non-Serious Adverse Drug Reactions, NSADRs</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 5    sadr                  Serious Adverse Drug Reactions, SADRs</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 6   susar Suspected Unexpected Serious Adverse Reactions, SUSARs</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
</code></pre></div>
    </div>
  </main><aside class="col-md-3"><nav id="toc" aria-label="Table of contents"><h2>On this page</h2>
    </nav></aside></div>


    <footer><div class="pkgdown-footer-left">
  <p>Developed by Alan G. Haynes, Mattia Branca.</p>
</div>

<div class="pkgdown-footer-right">
  <p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.1.1.</p>
</div>

    </footer></div>





  </body></html>

